We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Polivy

News List

Polivy® with R-CHP significantly improves lymphoma outcomes europeanpharmaceuticalreview
August 10, 2021
Polivy with MabThera/Rituxan and R-CHP is the first regimen in 20 years to improve significantly outcomes in a previously untreated form of lymphoma, Phase III study shows.
NICE does not recommend polatuzumab vedotin to treat lymphoma europeanpharmaceuticalreview
March 03, 2020
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL drugs
June 12, 2019
Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL.
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma drugs
June 11, 2019
FDA Grants Genentech’s Polivy (polatuzumab vedotin-piiq) Accelerated Approval for Adults With Previously Treated Aggressive Lymphoma.